The sexually transmitted papillomavirus infections: clinical manifestations, current and future therapies

Bibliography

• CATES W Jr: Estimates of the incidence and prevalence of sexually transmitted diseases in the US. American Social Health Association Panel. Sex. Transm. Dis. (1999) 26(Suppl.):4-7.
   PubMed Web of Science ®Google Scholar
• GERBERDING JL: Report to congress. Prevention of genital human papillomavirus infection. Centers for disease control and prevention, January (2004):1-35.
   Google Scholar
• CARTER JJ, KOUTSKY LA, HUGHES JP et al.: Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J. Infect. Dis. (2000) 181(6):1911-1919.
   PubMed Web of Science ®Google Scholar
• SLAVINSKY J III, KISSINGER P, BURGER L, BOLEY A, DICARLO RP, HAGENSEE ME: Seroepidemiology of low and high oncogenic risk types of human papillomavirus in a predominantly male cohort of STD clinic patients. Int. J. STD AIDS (2001) 12(8):516-523.
   PubMed Web of Science ®Google Scholar
• WIDEROFF L, SCHIFFMAN M, HADERER P et al.: Seroreactivity to human papillomavirus types 16, 18, 31, and 45 virus-like particles in a case-control study of cervical squamous intraepithelial lesions. J. Infect. Dis. (1999) 180(5):1424-1428.
   PubMed Web of Science ®Google Scholar
• STONE KM, KAREM KL, STERNBERG MR et al.: Seroprevalence of human papillomavirus type 16 infection in the US. J. Infect. Dis. (2002) 186(10):1396-1402.
   PubMed Web of Science ®Google Scholar
• STEVENS-SIMON C, NELLIGAN D, BREESE P, JENNY C, DOUGLAS JM Jr: The prevalence of genital human papillomavirus infections in abused and non-abused preadolescent girls. Pediatrics (2000) 106:645-649.
   PubMed Web of Science ®Google Scholar
• WINER RL, KOUTSKY LA: Human papillomavirus through the ages. J. Infect. Dis. (2005) 191:1787-1789.
   PubMed Web of Science ®Google Scholar
• SILVERBERG MJ, THORSEN P, LINDEBERG H, GRANT LA, SHAH KV: Condyloma in pregnancy is strongly predictive of juvenile-onset recurrent respiratory papillomatosis. Obstet. Gynecol. (2003) 101:645-652.
   PubMed Web of Science ®Google Scholar
• DUNNE EF, KAREM KL, STERNBERG MR et al.: Seroprevalence of human papillomavirus type 16 in children. J. Infect. Dis. (2005) 191:1817-1819.
   PubMed Web of Science ®Google Scholar
• SELLORS JW, KARWALAJTYS TL, KACZOROWSKI J et al.: Incidence, clearance and predictors of human papillomavirus infection in women. CMAJ (2003) 168(4):421-425.
   PubMed Web of Science ®Google Scholar
• WRIGHT JD, HERZOG TJ: Human papillomavirus: emerging trends in detection and management. Current Women’s Health Reports (2002) 2:259-265.
   PubMedGoogle Scholar
• UNGER ER, BUARTE-FRANCO E: Human papillomavirus into the new millennium. Obstet. Gynecol. Clin. North Am. (2001) 28:653-666.
   PubMed Web of Science ®Google Scholar
• KOUTSKY LA: Epidemiology of genital human papillomavirus infection. Am. J. Med. (1997) 102:3-8.
   PubMedGoogle Scholar
• HO GY, BIERMAN R, BEARDSLEY L, CHANG CJ, BURK RD: Natural history of cervicovaginal papillomavirus infection in young women. N. Engl. J. Med. (1998) 338:423-428.
   PubMed Web of Science ®Google Scholar
• HERRERO R, HILDESHEIM A, BRATTI C et al.: Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J. Natl. Cancer Inst. (2000) 92:464-474.
   PubMed Web of Science ®Google Scholar
• SIEGFRIED E, RASNICK-CONLEY J, COOK S, LEONARDI C, MONTELEONE J: Human papillomavirus screening in pediatric victims of sexual abuse. Pediatrics (1998) 101:43-47.
   PubMed Web of Science ®Google Scholar
• REVZINA NV, DICLEMENTE RJ: Prevalence and incidence of human papillomavirus infection in women in the US: a systematic review. Int. J. STD & AIDS (2005) 16(8):528-537.
   PubMed Web of Science ®Google Scholar
• MOSCICKI AB: Impact of HPV infection in adolescent population. J. Adolesc. Health (2005) 37(Suppl. 6):S3-S9.
   PubMed Web of Science ®Google Scholar
• BASEMAN JC, KOUTSKY LA: The epidemiology of human papillomavirus infections. J. Clin. Virol. (2005) 32(Suppl. 1):S16-S24.
   PubMed Web of Science ®Google Scholar
• JACOBS MV,WALBOOMERS JM, SNIJDERS PJ et al.: Distribution of 37 HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int. J. Cancer (2000) 87:221-227.
   PubMed Web of Science ®Google Scholar
• SCHIFFMAN M, CASTLE PE: Human papillomavirus. Epidemiology and public health. Arch. Pathol. Lab. Med. (2003) 127:930-934.
   PubMed Web of Science ®Google Scholar
• KJAER SK, SVARE EI, WORM AM, WALBOOMERS JM, MEIJER CJ, VAN DEN BRULE AJ: Human papillomavirus infection in Danish female sex workers: decreasing prevalence with age despite continuously high sexual activity. Sex. Transm. Dis. (2000) 27:438-445.
   PubMed Web of Science ®Google Scholar
• SHERMAN ME, LORINCZ AT, SCOTT DR et al.: Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J. Natl. Cancer. Inst. (2003) 95:46-52.
   PubMedGoogle Scholar
• LAZCANO-PONCE E, HERRERO R, MUNOZ N et al.: Epidemiology of HPV infection among Mexican women with normal cervical cytology. Int. J. Cancer (2001) 91:412-420.
   PubMed Web of Science ®Google Scholar
• WINER RL, LEE SK, HUGHES JP, ADAM DE, KIVIAT NB, KOUTSKY LA: Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am. J. Epidemiol. (2003) 157:218-226.
   PubMed Web of Science ®Google Scholar
• CASTLE PE, SCHIFFMAN M, HERRERO R et al.: A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J. Infect. Dis. (2005); 191:1808-1816.
   PubMed Web of Science ®Google Scholar
• HERRERO R, CASTLE PE, SCHIFFMAN M et al.: Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J. Infect. Dis. (2005) 191:1796-807.
   PubMed Web of Science ®Google Scholar
• WILEY DJ, DOUGLAS J, BEUTNER K et al.: External genital warts: diagnosis, treatment, and prevention. Clin. Infect. Dis. (2002) 35(Suppl. 2):S210-S224.
   Web of Science ®Google Scholar
• SVARE EI, KJAER SK, WORM AM, OSTERLIND A, MEIJER CJLM, VAN DEN BRULE AJ: Risk factors for genital HPV DNA in men resemble those found in women: a study of male attendees at a Danish STD clinic. Sex. Transm. Infect. (2002) 78:215-218.
   PubMed Web of Science ®Google Scholar
• KJAER SK, MUNK C, WINTHER JF, JORGENSEN HO, MEIJER CJ, VAN DEN BRULE AJ: Acquisition and persistence of human papillomavirus infection in younger men: a prospective follow-up study among Danish soldiers. Cancer Epidemiol. Biomarkers Prev. (2005) 14(6):1528-1533.
   PubMed Web of Science ®Google Scholar
• CHIN-HONG PV, VITTINGHOFF E, CRANSTON RD et al.: Age-specific prevalence of anal human papillomavirus infection in HIV-negative sexually active men who have sex with men: the EXPLORE study. J. Infect. Dis. (2004) 190:2070-2076.
   PubMed Web of Science ®Google Scholar
• GIULIANO AR, HARRIS R, SEDJO RL et al. Incidence, prevalence and clearance of type-specific human papillomavirus infections: The Young Women's Health Study. J. Infect. Dis. (2002) 186(4):462-469.
   PubMed Web of Science ®Google Scholar
• SCHEURER ME, TORTOLERO-LUNA G, ADLER-STORTHZ K et al.: Human papillomavirus infection: biology, epidemiology and prevention. Int. J. Gynecol. Cancer (2005) 15(5):727-746.
   PubMed Web of Science ®Google Scholar
• GREEN J, BERRINGTON DE GONZALES A, SMITH JS et al.: Human papillomavirus infection and use of oral contraceptives. Br. J. Cancer (2003) 88:1713-1720.
   PubMed Web of Science ®Google Scholar
• CASTELLSAGUE´ X, MUNOZ N: Cofactors in human papillomavirus carcinogenesis – role of parity, oral contraceptives and tobacco smoking. J. Natl. Cancer Inst. Monogr. (2003) 31:20-28.
   PubMedGoogle Scholar
• PALEFSKY JM, HOLLY EA: Immunosuppression and co-infection with HIV. J. Natl. Cancer Inst. Monogr. (2003) 31:41-46.
   Google Scholar
• MOSCICKI A-B, ELLENBERG JH, FARHAT S, XU J: Persistence of human papillomavirus infection in HIV-infected and -uninfected adolescent girls: risk factors and differences, by phylogenetic type. J. Infect. Dis. (2004) 190:37-45.
   PubMed Web of Science ®Google Scholar
• CRITCHLOW CW, HAWES SE, KUYPERS JM et al.: Effect of HIV infection on the natural history of anal human papillomavirus infection. AIDS (1998) 12:1177-1184.
   PubMed Web of Science ®Google Scholar
• PALEFSKY JM, HOLLY EA, RALSTON ML et al.: Prevalence and risk factors for human papillomavirus infection of the anal canal in HIV-positive and HIV-negative homosexual men. J. Infect. Dis. (1998) 177:361-367.
   PubMed Web of Science ®Google Scholar
• PIKETTY C, DARRAGH TM, HEARD I et al.: High prevalence of anal squamous intraepithelial lesions in HIV-positive men despite the use of highly active antiretroviral therapy. Sex. Transm. Dis. (2004) 31:96-99.
   PubMed Web of Science ®Google Scholar
• PALEFSKY JM, HOLLY EA, RALSTON ML et al.: Prevalence and risk factors for anal human papillomavirus infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. J. Infect. Dis. (2001) 183:383-391.
   PubMed Web of Science ®Google Scholar
• PIKETTY C, DARRAGH TM, DA COSTA M et al.: High prevalence of anal human papillomavirus infection and anal cancer precursors among HIV-infected persons in the absence of anal intercourse. Ann. Intern. Med. (2003) 138:453-459.
   PubMed Web of Science ®Google Scholar
• PIKETTY C, KAZATCHKINE MD: Human papillomavirus-related cervical and anal disease in HIV-infected individuals in the era of highly active antiretroviral therapy. Curr. HIV/AIDS Rep. (2005) 2(3):140-145.
   PubMedGoogle Scholar
• BOSCH FX, LORINCZ A, MUNOZ N, MEIJER CJ, SHAH KV: The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. (2002) 55:244-265.
   PubMed Web of Science ®Google Scholar
• BOSCH FX: Epidemiology of human papillomavirus infections: New options for cervical cancer prevention. Salud Publica Mex. (2003) 45(Suppl. 3):S326-S339.
   Google Scholar
• CASTLE PE, WACHOLDER S, SHERMAN ME et al.: A prospective study of highgrade cervical neoplasia among human papillomavirus-infected women. J. Natl. Cancer Inst. (2002) 94:1406-1414.
   PubMed Web of Science ®Google Scholar
• CASTELLSAGUÉ X, GHAFFARI A, DANIEL RW, BOSCH FX, MUÑOZ N, SHAH KV: Prevalence of penile human papillomavirus DNA in husbands of women with and without cervical neoplasia: a study in Spain and Colombia. J. Infect. Dis. (1997) 176:353-361.
   PubMed Web of Science ®Google Scholar
• THOMAS DB, RAY RM, KUYPERS J et al.: Human papillomaviruses and cervical cancer in Bangkok. III. Role of husbands and commercial sex workers. Am. J. Epidemiol. (2001) 153(8):740-748.
   PubMed Web of Science ®Google Scholar
• CASTELLSAGUÉ X, BOSCH FX, MUNOZ N et al.: Male circumcision, penile human papillomavirus infection and cervical cancer in female partners. N. Engl. J. Med. (2002) 346:1105-1112.
   PubMed Web of Science ®Google Scholar
• BOSCH FX, DE SANJOSÉ S: Human papillomavirus and cervical cancer-burden and assessment of causality. J. Natl. Cancer Inst. Monogr. (2003) 31:3-13.
   PubMedGoogle Scholar
• MYERS ER, MCCRORY DC, NANDA K, BASTIAN L, MATCHAR DB: Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am. J. Epidemiol. (2000) 151(12):1158-1117.
   PubMed Web of Science ®Google Scholar
• WALBOOMERS JM, JACOBS MV, MANOS MM et al.: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. (1999) 189:12-19.
   PubMed Web of Science ®Google Scholar
• BAUER HM: Genital human papillomavirus infection. National Network of STD/HIV Prevention Training Centers. June (2004):1-23.
   Google Scholar
• PARKIN DM, WHELAN SL, FERLAY J, RAYMOND R, YOUNG J (Eds): Cancer incidence in five continents. International Agency for Research on Cancer, Lyon, France (1997) Scientific publication no. 143 vol.VII.
   Google Scholar
• FERLAY J, BRAY F, PISANI P, PARKIN DM (Eds): Globocan (2000): Cancer incidence, mortality and prevalence worldwide, version 1.0. IARC cancer-base no. 5. International Agency for Research on Cancer, Lyon, France (2001).
   Google Scholar
• RIES L, KOSERY C, HANKEY B, MILLERB, CLEGG L, EDWARDS B: SEER cancer statistics review 1973 – 1996. National Cancer Institute, Bethesda, MD (1999).
   Google Scholar
• SCHIFFMAN M, KRÜGER KS: Natural history of anogenital human papillomavirus infection and neoplasia. J. Natl. Cancer Inst. Monogr. (2003) 31:14-19.
   PubMedGoogle Scholar
• MELBYE M, RABKIN C, FRISCH M, BIGGAR RJ: Changing patterns of anal cancer incidence in the US, 1940 – 1989. Am. J. Epidemiol. (1994) 139:772-780.
   PubMed Web of Science ®Google Scholar
• KOBLIN BA, HESSOL NA, ZAUBER AG et al.: Increased incidence of cancer among homosexual men, New York City and San Francisco, 1978 – 1990. Am. J. Epidemiol. (1996) 144(10):916-923.
   PubMed Web of Science ®Google Scholar
• PANTHER LA, SCHLECHT HP, DEZUBE BJ: Spectrum of human papillomavirus-related dysplasia and carcinoma of the anus in HIV-infected patients. AIDS Read. (2005) 15(2):79-91.
   PubMedGoogle Scholar
• FRISCH M, SMITH E, GRULICH A et al.: Cancer in a population-based cohort of men and women in registered homosexual partnerships. Am. J. Epidemiol. (2003) 157:966-972.
   PubMed Web of Science ®Google Scholar
• GOEDERT JJ, COTE TR, VIRGO O et al.: Spectrum of AIDS-associated malignant disorders. Lancet (1998) 351:1833.
   PubMed Web of Science ®Google Scholar
• HOLLY EA, RALSTON ML, DARRAGH TM et al.: Prevalence and risk factors for anal squamous intraepithelial lesions in women. J. Natl. Cancer Inst. (2001) 93:843-849.
   PubMedGoogle Scholar
• FRISCH M, BIGGAR RJ, GOEDERT JJ: Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J. Natl. Cancer Inst. (2000) 92:1522-1528.
   PubMedGoogle Scholar
• PALEFSKY JM, HOLLY EA, EFIRDC JT et al.: Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men. AIDS (2005) 19(13):1407-1414.
   PubMed Web of Science ®Google Scholar
• KREIMER AR, CLIFFORD GM, BOYLE P, FRANCESCHI S: Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol. Biomarkers Prev. (2005) 14(2):467-475.
   PubMed Web of Science ®Google Scholar
• ROSENBLATT KA, CARTER JJ, IWASAKI LM, GALLOWAY DA, STANFORD JL: Serologic evidence of human papillomavirus 16 and 18 infections and risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. (2003) 12(8):763-768.
   PubMed Web of Science ®Google Scholar
• ADAMI HO, KUPER H, ANDERSSON SO, BERGSTROM R, DILLNER J: Prostate cancer risk and serologic evidence of human papilloma virus infection: a population-based case-control study. Cancer Epidemiol. Biomarkers Prev. (2003) 12(9):872-875.
   PubMed Web of Science ®Google Scholar
• YAMADA T, MANOS MM, PETO J et al.: Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. J. Virol. (1997) 71:2463-2472.
   PubMed Web of Science ®Google Scholar
• DE VILLIERS EM: Human papillomavirus: introduction. Semin. Cancer Biol. (1999) 9:377.
   PubMed Web of Science ®Google Scholar
• HILDESHEIM A, SCHIFFMAN M, BROMLEY C et al.: Human papillomavirus type 16 variants and risk of cervical cancer. J. Natl. Cancer Inst. (2001) 93:315-318.
   Google Scholar
• MUNOZ N, BOSCH FX, DE SANJOSE S et al.: Epidemiologic classification of human papillomavirus types associated with cervical cancer. New Engl. J. Med. (2003) 348:518-527.
   PubMed Web of Science ®Google Scholar
• GISSMANN L, BOSHART M, DURST M, IKENBERG H,WAGNER D, ZUR HAUSEN H: Presence of human papillomavirus in genital tumors. J. Invest. Dermatol. (1984) 83:26S-28S.
   PubMed Web of Science ®Google Scholar
• CARTER JJ, MADELEINE MM, SHERA K et al.: Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Res. (2001) 61:1934-1940.
   PubMed Web of Science ®Google Scholar
• HO GY, BURK RD, FLEMING I, KLEIN RS: Risk of genital human papillomavirus infection in women with human immunodeficiency virus-induced immunosuppression. Int. J. Cancer (1994) 56:788-792.
   PubMed Web of Science ®Google Scholar
• VOLTER C, HE Y, DELIUS H et al.: Novel HPV types present in oral papillomatous lesions from patients with HIV infection. Int.J. Cancer (1996) 66:453-456.
   PubMed Web of Science ®Google Scholar
• FORSLUND O, NORDIN P, ANDERSSON K, STENQUIST B, HANSSON BG: DNA analysis indicates patient-specific human papillomavirus type 16 strains in Bowen’s disease on fingers and in archival samples from genital dysplasia. Br.J. Dermatol. (1997) 136:678-682.
   PubMed Web of Science ®Google Scholar
• ARANY I, EVANS T, TYRING SK: Tissue specific HPV expression and downregulation of local immune responses in condylomas from HIV seropositive individuals. Sex. Transm. Infect. (1998) 74:349-353.
   PubMed Web of Science ®Google Scholar
• STUBENRAUCH F, LAIMINS LA: Human papillomavirus life cycle: active and latent phases. Semin. Cancer Biol. (1999) 9:379-386.
   PubMed Web of Science ®Google Scholar
• HONG K, GREER CE, KETTER N, VAN NEST G, PALIARD X: Isolation and characterization of human papillomavirus type 6-specific T cells infiltrating genital warts. J. Virol. (1997) 71:6427-6432.
   PubMed Web of Science ®Google Scholar
• BEUTNER K, WILEY D: Recurrent external genital warts: a literature review. Papillomavirus Report (1997) 8:69-74.
   Google Scholar
• BEUTNER KR, RICHWALD GA, WILEY DJ, REITANO MV: External genital warts: report of the American Medical Association Consensus Conference. AMA Expert Panel on External Genital Warts. Clin. Infect. Dis. (1998) 27:796-806.
   PubMed Web of Science ®Google Scholar
• BEUTNER KR, WILEY DJ, DOUGLAS JM et al.: Genital warts and their treatment. Clin. Infect. Dis. (1999) 28(Suppl. 1):S37-S56.
   PubMedGoogle Scholar
• WANG SS, HILDESHEIM A: Viral and host factors in human papillomavirus persistence and progression. J. Natl. Cancer Inst. Monogr. (2003) 31:35-40.
   Google Scholar
• FRANCO EL, VILLA LL, SOBRINHO JP et al.: Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J. Infect. Dis. (1999) 180(5):1415-1423.
   PubMed Web of Science ®Google Scholar
• MOSCICKI AB, SHIBOSKI S, BROERING J et al.: The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J. Ped. (1998) 132(2):277-284.
   PubMed Web of Science ®Google Scholar
• MOLANO M, VAN DEN BA, PLUMMER M et al.: Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am. J. Epidemiol. (2003) 158(5):486-494.
   PubMed Web of Science ®Google Scholar
• FERENCZY A, FRANCO E: Persistent human papillomavirus infection and cervical neoplasia. Lancet Oncol. (2002) 3:11-16.
   PubMed Web of Science ®Google Scholar
• NOBBENHUIS MA, HELMERHORST TJ, VAN DEN BRULE AJ et al.: Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet (2001) 358:1782-1783.
   PubMed Web of Science ®Google Scholar
• SCHIFFMAN M, WHEELER CM, PHILIP E: Human papillomavirus DNA remains detectable longer than related cervical cytologic abnormalities. J. Infect. Dis. (2002) 186:1169-72.
   PubMed Web of Science ®Google Scholar
• SCHLECHT NF, PLATT RW, DUARTE-FRANCO E et al.: Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J. Natl. Cancer Inst. (2003) 95(17):1336-1343.
   PubMedGoogle Scholar
• MOSCICKI AB, HILLS N, SHIBOSKI S et al.: Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA (2001) 285:2995-3002.
   PubMed Web of Science ®Google Scholar
• KOUTSKY LA, HOLMES KK, CRICHTCHLOW CW et al.: A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. New Engl. J. Med. (1992) 327(18):1272-1278.
   PubMed Web of Science ®Google Scholar
• MUNOZ N: Human papillomavirus and cancer: the epidemiological evidence. J. Clin. Virol. (2000) 19(1-2):1-5.
   PubMed Web of Science ®Google Scholar
• HILDESHEIM A, HERRERO R, CASTLE PE et al.: HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica. Br. J. Cancer (2001) 84:1219-1226.
   PubMed Web of Science ®Google Scholar
• CASTLE PE, GIULIANO AR: Genital tract infections, cervical inflammation, and antioxidant nutrients – assessing their roles as human papillomavirus cofactors. J. Natl Cancer Inst. (2003) 31:29-34.
   Google Scholar
• SMITH JS, GREEN J, BERRINGTON DG et al.: Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet (2003) 361:1159-1167.
   PubMed Web of Science ®Google Scholar
• SMITH JS, MUNOZ N, HERRERO R et al.: Evidence for Chlamydia trachomatis as a human papillomavirus cofactor in the etiology of invasive cervical cancer in Brazil and the Philippines. J. Infect. Dis. (2002) 185:324.
   PubMed Web of Science ®Google Scholar
• RODEN RB, LOWY DR, SCHILLER JT: Papillomavirus is resistant to desiccation. J. Infect. Dis. (1997) 176:1076-1079.
   PubMed Web of Science ®Google Scholar
• CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC): Department of Health and Human Services. Fact sheet for public health personnel: male latex condoms and sex. Trans. Dis. (2001).
   Google Scholar
• MARRAZZO JM, KOUTSKY LA, KIVIAT NB, KUYPERS JM, STINE K: Papanicolaou test screening and prevalence of genital human papillomavirus among women who have sex with women. Am. J. Public Health (2001) 91:947-952.
   PubMed Web of Science ®Google Scholar
• KJAER SK, CHACKERIAN B, VAN DEN BRULE AJ et al.: High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse). Cancer Epidemiol. Biomarkers Prev. (2001) 10:101-106.
   PubMed Web of Science ®Google Scholar
• BURK RD, HO GY, BEARDSLEY L, LEMPA M, PETERS M, BIERMAN R: Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women. J. Infect. Dis. (1996) 174:679-689.
   PubMed Web of Science ®Google Scholar
• SONNEX C, STRAUSS S, GRAY JJ: Detection of human papillomavirus DNA on the fingers of patients with genital warts. Sex. Transm. Infect. (1999) 75(5):317-319.
   PubMed Web of Science ®Google Scholar
• FORSLUND O, NORDIN P, HANSSON BG: Mucosal human papillomavirus types in squamous cell carcinoma of the uterine cervix and subsequently on fingers. Br. J. Dermatol. (2000) 142(6):1148-1153.
   PubMed Web of Science ®Google Scholar
• ALAM M, CALDWELL JB, ELIEZRI YD: Human papillomavirus-associated digital squamous cell carcinoma: literature review and report of 21 new cases. J. Am. Acad. Dermatol. (2003) 48(3):385-393.
   PubMed Web of Science ®Google Scholar
• RUDLINGER R, GROB R, YU YX, SCHNYDER UW: Human papillomavirus-35-positive bowenoid papulosis of the anogenital area and concurrent human papillomavirus-35-positive verruca with bowenoid dysplasia of the periungual area. Arch. Dermatol. (1989) 125:655-659.
   PubMedGoogle Scholar
• BOXMAN IL, HOGEWONING A, MULDER LH, BOUWES BAVINCK JN, TER SCHEGGET J: Detection of human papillomavirus types 6 and 11 in pubic and perianal hair from patients with genital warts. J. Clin. Microbiol. (1999) 37:2270-2273.
   PubMed Web of Science ®Google Scholar
• PURANEN M, SYRJANEN K, SYRJANEN S: Transmission of genital human papillomavirus infections is unlikely through the floor and seats of humid dwellings in countries of high-level hygiene. Scand. J. Infect. Dis. (1996) 28(3):243-246.
   PubMed Web of Science ®Google Scholar
• STRAUSS S, SASTRY P, SONNEX C, EDWARDS S, GRAY J: Contamination of environmental surfaces by genital human papillomaviruses. Sex. Transm. Infect. (2002) 78:135-138.
   PubMed Web of Science ®Google Scholar
• STRAUSS S, STEPHEN H, SONNEX C, GRAY J: Contamination of environmental surfaces by genital human papillomaviruses (HPV): a follow up study. Sex. Transm. Infect. (2003) 79:426-427.
   PubMed Web of Science ®Google Scholar
• DILLNER J, ANDERSSON-ELLSTROM A, HAGMAR B, SCHILLER J: High risk genital papillomavirus infections are not spread vertically. Rev. Med. Virol. (1999) 9:23-29.
   PubMed Web of Science ®Google Scholar
• SYRIANEN S, PURANEN M: Human papillomavirus infection in children: the potential role of maternal transmission. Crit. Rev. Oral Biol. Med. (2000) 11(2):259-274.
   PubMedGoogle Scholar
• PURANEN M, YLISKOSKI M, SAARIKOSKI S, SYRJANEN K, SYRJANEN S: Vertical transmission of human papillomavirus from infected mothers to their newborn babies and persistence of the virus in childhood. Am. J. Obstet. Gynecol. (1996) 174:694-699.
   PubMed Web of Science ®Google Scholar
• RICE PS, CASON J, BEST JM, BANATVALA JE: High risk genital papillomavirus infections are spread vertically. Rev. Med. Virol. (1999) 9(1):15-21.
   PubMed Web of Science ®Google Scholar
• WATTS DH, KOUTSKY LA, HOLMES KK et al.: Low risk of perinatal transmission of human papillomavirus: results from a prospective cohort study. Am. J. Obstet. Gynecol. (1998) 178:365-373.
   PubMed Web of Science ®Google Scholar
• SMITH EM, RITCHIE JM, YANKOWITZ J et al.: Human papillomavirus prevalence and types in newborns and parents: concordance and modes of transmission. Sex. Transm. Dis. (2004) 31:57-62.
   PubMed Web of Science ®Google Scholar
• COHEN BA: Warts and children: can they be separated? Contemp. Ped. (1997) 14:128-149.
   Google Scholar
• ADAMS JA: Evolution of a classification scale: medical evaluation of suspected child sexual abuse. Child Maltreat. (2001) 6:31-35.
   PubMedGoogle Scholar
• DEJESUS LE, LIMA OL, NETO C, DO NASCIMENTO LM, ARAUJO RC, BAPTISTA AA: Anogenital warts in children: sexual abuse or unintentional contamination? Cadernos de Saude Publica (2001) 17:1383-1391.
   PubMedGoogle Scholar
• FRAZIER L: Genital warts in children. Am. Prof. Soc. Abuse Children Ad. (1998) 11:9-12.
   Google Scholar
• RINTALA MA, GRENMAN SE, PURANEN MH et al.: Transmission of high-risk human papillomavirus (HPV) between parents and infant: a prospective study of HPV in families in Finland. J. Clin. Microbiol. (2005) 43:376-381.
   PubMed Web of Science ®Google Scholar
• CASON J, KAYE JN, JEWERS RJ et al.: Perinatal infection and persistence of human papillomavirus type 16 and 18 in infants. J. Med. Virol. (1995) 47:209-218.
   PubMed Web of Science ®Google Scholar
• CASON J, MANT CA: High-risk mucosal human papillomavirus infections during infancy and childhood. J. Clin. Virol. (2005) 32(S1):S52-S58.
   PubMedGoogle Scholar
• EGBERT JE, KERSTEN RC: Female genital tract papillomavirus in conjuctival papillomas of infancy. Am. J. Ophthalmol. (1997) 123(4):551-552.
   PubMed Web of Science ®Google Scholar
• MOSCICKI AB, WINKLER B, IRWIN C, SCHACHTER J: Differences in biologic maturation, sexual behavior and sexually transmitted disease between adolescents with and without cervical intraepithelial neoplasia. J. Pediatr. (1989) 115:487-493.
   PubMed Web of Science ®Google Scholar
• SHEW M, FORTENBERRY J, MILES P, AMORTEGUL A: Interval between menarche and first sexual intercourse, related to risk of human papillomavirus infection. J. Pediatr. (1994) 125:661-666.
   PubMed Web of Science ®Google Scholar
• WIATRAK BJ: Overview of recurrent respiratory papillomatosis. Curr. Opin. Otolaryngol. Head Neck Surg. (2003) 11(6):433-441.
   PubMedGoogle Scholar
• HERRERO R: Human papillomavirus and cancer of the upper aerodigestive tract. J. Natl Cancer Inst. Monogr. (2003) 31:47-51.
   PubMedGoogle Scholar
• DILORENZO TP, STEINBERG BM: Differential regulation of human papillomavirus type 6 and 11 early promoters in cultured cells derived from laryngeal papillomas. J. Virol. (1995) 69:6865-6872.
   PubMed Web of Science ®Google Scholar
• NUNEZ DA, ASTLEY SM, LEWIS FA, WELLS M: Human papilloma viruses: a study of their prevalence in the normal larynx. J. Laryngol. Otol. (1994) 108:319-320.
   PubMed Web of Science ®Google Scholar
• SYRIANEN S: Human papillomavirus (HPV) in head and neck cancer. J.Clin.Virol. (2005) 32:S59-S66.
   Google Scholar
• GLOSTER HM Jr, ROENIGK RK: Risk of acquiring human papillomavirus from the plume produced by the carbon dioxide laser in the treatment of warts. J. Am. Acad. Dermatol. (1995) 32:436-441.
   PubMed Web of Science ®Google Scholar
• CALERO L, BRUSIS T: Laryngeal papillomatosis – first recognition in Germany as an occupational disease in an operating room nurse. Laryngorhingootologie (2003) 82(11):790-793.
   PubMed Web of Science ®Google Scholar
• ABBY C: Hearing addresses condoms for HPVprevention. J. Natl Cancer Inst. (2004) 96:985.
   PubMedGoogle Scholar
• BLEEKER MCG, HOGEWONING CJA, VOORHORST FJ et al.: Condom use promotes regression of human papillomavirus-associated penile lesions in male sexual partners of women with cervical intraepithelial neoplasia. Int. J. Cancer (2003) 107:804-810.
   PubMed Web of Science ®Google Scholar
• HOGEWONING CJ, BLEEKER MC, VAN DEN BRULE AJ et al.: Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomised clinical trial. Int. J. Cancer (2003) 107:811-816.
   PubMed Web of Science ®Google Scholar
• DE VILLIERS EM, FAUQUET C, BROKER TR, BERNARD HU, ZUR HAUSEN H: Classification of papillomaviruses. Virology (2004) 324(1):17-27.
   PubMed Web of Science ®Google Scholar
• SONNEX C: Human papillomavirus infection with particular reference to genital disease. J. Clin. Pathol. (1998) 51:643-648.
   PubMed Web of Science ®Google Scholar
• BERG M, STENLUND A: Functional interactions between papillomavirus E1 and E2 proteins. J. Virol. (1997) 71:3853-3863.
   PubMed Web of Science ®Google Scholar
• DESAINTES C, DEMERET C, GOYAT S et al.: Expression of the papillomavirus E2 protein in HeLa cells leads to apoptosis. EMBO J. (1997) 16:504-514.
   PubMed Web of Science ®Google Scholar
• BOSCH FX, ROHAN T, SCHNEIDER A et al.: Papillomavirus research update: highlights of the Barcelona HPV (2000) international papillomavirus conference. J. Clin. Pathol. (2001) 54:163-175.
   PubMed Web of Science ®Google Scholar
• DE RODA HUSMAN AM, WALBOOMERS JM, VAN DEN BRULE AJ, MEIJER CJ, SNIJDERS PJ: The use of general primers GP5 and GP6 elongated at their 3-ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J. Gen. Virol. (1995) 76:1057-1062.
   PubMed Web of Science ®Google Scholar
• STANLEY MA: Human papillomavirus and cervical carcinogenesis. Best Pract. Res. Clin. Obstet. Gynaecol. (2001) 15:663-676.
   PubMed Web of Science ®Google Scholar
• STANLEY M: Genital human papillomavirus infections – current and prospective therapies. J. Natl. Cancer Inst. Monogr. (2003) 31:117-124.
   PubMedGoogle Scholar
• MCMILLAN NA, PAYNE E, FRAZER IH, EVANDER M: Expression of the α6 integrin confers papillomavirus binding upon receptor-negative B-cells. Virology (1999) 261:271-279.
   PubMed Web of Science ®Google Scholar
• JOYCE JG, TUNG JS, PRZYSIECKI CT et al.: The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J. Biol. Chem. (1999) 274:5810-5822.
   PubMed Web of Science ®Google Scholar
• MARAN A, AMELLA CA, DI LORENZO TP, AUBORN KJ, TAICHMAN LB, STEINBERG BM: Human papillomavirus type 11 transcripts are present at low abundance in latently infected respiratory tissues. Virology (1995) 212:285-294.
   PubMed Web of Science ®Google Scholar
• COX JT, SCHIFFMAN M, SOLOMON DS (for the ALTS Group): Prospective follow-up suggests similar risk of subsequent high-grade CIN among women with CIN 1 or negative colposcopically-directed biopsy. Am. J. Obstet. Gynecol. (2007) in press.
   Google Scholar
• JOSEFSSON AM, MAGNUSSON PKE, YLITALO N et al.: Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet (2000) 355:2189-2193.
   PubMed Web of Science ®Google Scholar
• YLITALO N, SORENSEN P, JOSEFSSON AM et al.: Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet (2000) 355:2194-2198.
   PubMed Web of Science ®Google Scholar
• MCMILLAN A, OGILVIE MM: Human papillomavirus infection. Ch5, Sec2: viral infections. In: Clinical practice in sexually transmissible infections, 1st edn. McMillan A, Young H, Ogilvie MM, Scott GR (Eds). Saunders Ltd, Edinburgh (2002):71-105.
   Google Scholar
• ORIEL JD: Natural history of genital warts. Br. J. Vener. Dis. (1971) 47:1-13.
   PubMedGoogle Scholar
• GROSS G, PFISTER H: Role of human papillomavirus in penile cancer, penile intraepithelial squamous cell neoplasias and in genital warts. Med. Microbiol. Immunol. (2004) 193:35-44.
   PubMed Web of Science ®Google Scholar
• VON KROGH G, GROSS G, BARRASSO R: Warts and HPV-related squamous cell tumors of the genitoanal area in adults. In: Human papillomavirus infections in dermatovenereology. Gross G, Von Krogh (Eds). CRC Press, Boca Raton (1997):259-304.
   Google Scholar
• MAJEWSKI S, JABLONSKA S: Human papillomavirus-associated tumors of the skin and mucosa. J. Am. Acad. Dermatol. (1997) 36:659-685.
   PubMed Web of Science ®Google Scholar
• MYHRE AK, DALEN A, BERNTZEN K, BRATLID D: Anogenital human papillomavirus in non-abused preschool children. Acta. Paediatrica. (2003) 92:1445-1452.
   PubMed Web of Science ®Google Scholar
• REAGAN JW, SEIDEMANN IL, SARACUSA Y: Cellular morphology of carcinoma in situ and dysplasia or atypical hyperplasia of uterine cervix. Cancer (1953) 6:224-225.
   PubMed Web of Science ®Google Scholar
• RICHART RM: Natural history of cervical intraepithelial neoplasia. Clin. Obstet. Gynecol. (1968) 10:748-784.
   Google Scholar
• NATIONAL CANCER INSTITUTE WORKSHOP: The 1998 Bethesda System for reporting cervical/vaginal cytologic diagnoses. JAMA. (1989) 262:931-934.
   PubMed Web of Science ®Google Scholar
• THE BETHESDA SYSTEM FOR REPORTING CERVICAL/VAGINAL CYTOLOGIC DIAGNOSES: Revised after the second National Cancer Institute Workshop, April 29 – 30 1991. Acta Cytol. (1993) 37:115-24.
   PubMed Web of Science ®Google Scholar
• PARTRIDGE JM, KOUTSKY LA: Genital human papillomavirus infection in men. Lancet Infect. Dis. (2006) 6:21-31.
   PubMed Web of Science ®Google Scholar
• IKENBERG H, GISSMANN L, GROSS G et al.: Human papillomavirus type 16-related DNA in genital Bowen’s disease and in bowenoid papulosis. Int. J. Cancer (1983) 32:563-565.
   PubMed Web of Science ®Google Scholar
• BROWN TJ, YEN-MOORE A, TYRING SK: An overview of sexually transmitted diseases. Part II. J. Am. Acad. Dermatol. (1999) 41:661-677.
   PubMed Web of Science ®Google Scholar
• GOUMOUSAS-MICHAEL M, GIOLAMA E, GOUMOUSAS N, GIOLAMAG: Genital human papillomavirus infection and associated penile intraepithelial neoplasia in males infected with the human immunodeficiency virus. Acta. Cytol. (2000) 44:305-309.
   PubMed Web of Science ®Google Scholar
• MICALI G, NASCA MR, INNOCENZI D, SCHWARTZ RA: Penile cancer. J. Am. Acad. Dermatol. (2006) 54:369-391.
   PubMed Web of Science ®Google Scholar
• MURAO K, KUBO Y, FUKUHARA K, MATSUMOTO K, ARASE S: Three cases of Bowen’s disease on the lower abdomen associated with high-risk types 16, 33 and 59 of human papillomavirus. J. Am. Acad. Dermatol. (2005) 52:723-724.
   PubMed Web of Science ®Google Scholar
• ENGLISH JC, LAWS RA, KEOUGH GC, WILDE JL, FOLEY JP, ELSTON DM: Dermatoses of the glans penis and prepuce. J. Am. Acad. Dermatol. (1997) 37:1-24.
   PubMed Web of Science ®Google Scholar
• QUEYRAT L: Erythroplasie du gland. Bull. Soc. Fr. Dermatol. Syphiligr. (1911) 22:378-382.
   Google Scholar
• MITSUISHI T, SATA T, IWASAKI T et al.: The detection of human papillomavirus 16 DNA in erythroplasia of Queyrat invading the urethra. Br. J. Dermatol. (1998) 138:188-189.
   PubMed Web of Science ®Google Scholar
• WIELAND U, JURK S, WEISSENBORN S, KRIEG T, PFISTER H, RITZKOWSKY A: Erythroplasia of Queyrat: coinfection with cutaneous carcinogenic human papillomavirus type 8 and genital papillomaviruses in a carcinoma in situ. J. Invest. Dermatol. (2000) 115:396-401.
   PubMed Web of Science ®Google Scholar
• RUBIN MA, KLETER B, ZHOU M et al.: Detection and typing of human papillomavirus DNA in penile carcinoma. Evidence for multiple independent pathways of penile carcinogenesis. Am. J. Pathol. (2001) 159:1211-1218.
   PubMed Web of Science ®Google Scholar
• DUPIN N: Genital warts. Clin. Dermatol. (2004) 22:481-486.
   PubMed Web of Science ®Google Scholar
• BUFFET M, AYNAUD O, PIRON D et al.: Buschke–Lowenstein penile tumor. Prog. Urol. (2002) 12:332-336.
   PubMed Web of Science ®Google Scholar
• JABLONSKA S, OBALEK S, ORTH G et al.: Tumeur géante de Buschke–Lowenstein à PVH 6 avec metastases dans la paroi abdominale. Ann. Dermatol. Venereol. (1988) 115:1201-1202.
   PubMed Web of Science ®Google Scholar
• GRASSEGGER A, HÖPFL R, HUSSL H et al.: Buschke-Lowenstein tumor infiltrating pelvic organs. Br. J. Dermatol. (1994) 130:221-225.
   PubMed Web of Science ®Google Scholar
• BOGOMOLETZ WW, POTET F, MOALS G: Condylomata acuminata, giant condyloma acuminatum (Buschke–Lowenstein tumour) and verrucous squamous carcinoma of the perianal and ano-rectal region: a continuous precancerous spectrum? Histopathology (1985) 9:1155-1169.
   PubMed Web of Science ®Google Scholar
• DE CLERCQ E: Recent highlights in the development of new antiviral drugs. Curr. Opin. Microbiol. (2005) 8:552-560.
   PubMed Web of Science ®Google Scholar
• DE CLERCQ E: Antiviral drug discovery and development: where chemistry meets with biomedicine. Antiviral Res. (2005) 67:56-75.
   PubMed Web of Science ®Google Scholar
• DE CLERCQ E, HOLY A: Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat. Rev. Drug Discov. (2005) 4:928-940.
   PubMed Web of Science ®Google Scholar
• SNOECK R, VAN RANST M, ANDREI G et al.: Treatment of anogenital papillomavirus infections with an acyclic nucleoside phosphonate analogue. New Engl. J. Med. (1995) 333:943-944.
   PubMed Web of Science ®Google Scholar
• DOUGLAS J, COREY T, TYRING S et al.: A Phase I/II study of cidofovir topical gel for refractory condyloma acuminatum in patients with HIV infection. Presented at: 4th Conference on Retroviruses and Opportunistic Infections; January 22 – 26, (1997) Washington DC, US.
   Google Scholar
• SNOECK R, BOSSENS M, PARENT D et al.: Phase II doubleblind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection. Clin. Infect. Dis. (2001) 33:597-602.
   PubMed Web of Science ®Google Scholar
• SCHURMANN D, BERGMANN F, TEMMESFELD-WOLLBRUCK B, GROBUSCH MP, SUTTORP N: Topical cidofovir is effective in treating extensive penile condylomata acuminata. AIDS (2000) 14:1075-1076.
   PubMed Web of Science ®Google Scholar
• GRONE D, TREUDLER R, DE VILLIERS EM, HUSAK R, ORFANOS CE, ZOUBOULIS CC: Intravenous cidofovir treatment for recalcitrant warts in the setting of a patient with myelodysplastic syndrome. Eur. Acad. Dermatol. Venereol. (2006) 20:202-205.
   PubMed Web of Science ®Google Scholar
• SNOECK R, NOEL JC, MULLER C, DE CLERCQ E, BOSSENS M: Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III). J. Med. Virol. (2000) 60:205-209.
   PubMed Web of Science ®Google Scholar
• SNOECK R, VAN LAETHEM Y, DE CLERCQ E, DE MAUBEUGE J, CLUMECK N: Treatment of a bowenoid papulosis of the penis with local applications of cidofovir in a patient with acquired immunodeficiency syndrome. Arch. Intern. Med. (2001) 161:2382-2384.
   PubMedGoogle Scholar
• DE CLERCQ E: Acyclic nucleoside phosphonates: past, present and future bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge. Biochem. Pharmacol. (2006) in press.
   Google Scholar
• HOSTETLER KY, ROUGHT S, ALDERN KA, TRAHAN J, BEADLE JR, CORBEIL J: Enhanced antiproliferative effects of alkoxyalkyl esters of cidofovir in human cervical cancer cells in vitro. Mol. Cancer Ther. (2006) 5:156-159.
   PubMed Web of Science ®Google Scholar
• NIWA K, TAGAMI K, LIAN Z, GAO J, MORI H, TAMAYA T: Topical vidarabine or 5-fluorouracil treatment against persistent HPV in genital (pre)cancerous lesions. Oncol. Rep. (2003) 10:1437-1441.
   PubMed Web of Science ®Google Scholar
• GARCIA-LOPEZ P, COLL M, CERVERA E et al.: The systemic absorption of etoposide after intravaginal administration in patients with cervical intraepithelial lesions associated with human papillomavirus infection. Pharm. Res. (2006) 23:378-383.
   PubMed Web of Science ®Google Scholar
• NARAYANAN BA, HOLLADAY EB, NIXON DW, MAURO CT: The effect of all-trans and 9-cis retinoic acid on the steady state level of HPV16 E6/E7 mRNA and cell cycle in cervical carcinoma cells. Life Sci. (1998) 63:565-573.
   PubMed Web of Science ®Google Scholar
• SUN SY, YUE P, HONG WK, LOTAN R: Induction of Fas expression and augmentation of Fas/Fas ligand-mediated apoptosis by the synthetic retinoid CD437 in human lung cancer cells. Cancer Res. (2000) 60:6537-6543.
   PubMed Web of Science ®Google Scholar
• MEYSKENS FL Jr, SURWIT E, MOON TE et al.: Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans retinoic acid: a randomized trial. J. Natl. Cancer Inst. (1994) 86:539-543.
   PubMed Web of Science ®Google Scholar
• RUIDI C, AIHUA D, PEIYU B et al.: Chemoprevention of cancer of uterine cervix: a study on chemoprevention of retinamide II from cervical precancerous lesions. J. Cell Biochem. Suppl. (1997) 28-29:140-143.
   PubMedGoogle Scholar
• AHN WS, LEE JM, NAMKOONG SE, LEE HY, KIM SJ: Effect of retinoic acid on HPV titration and colposcopic changes in Korean patients with dysplasia of the uterine cervix. J. Cell Biochem. Suppl. (1997) 28-29:133-139.
   PubMedGoogle Scholar
• RUFFIN MT, BAILEY JM, NORMOLLE DP et al.: Low-dose topical delivery of all-trans retinoic acid for cervical intraepithelial neoplasia II and III. Cancer Epidemiol. Biomarkers Prev. (2004) 13(12):2148-52.
   PubMed Web of Science ®Google Scholar
• ALVAREZ RD, CONNER MG, WEISS H et al.: The efficacy of 9-cis-retinoic acid (aliretinoin) as a chemopreventive agent for cervical dysplasia: results of a randomized double-blind clinical trial. Cancer Epidemiol. Biomarkers Prev. (2003) 12:114-119.
   PubMed Web of Science ®Google Scholar
• GEORGALA S, KATOULIS AC, GEORGALA C, BOZI E, MORTAKIS A: Oral isotretinoin in the treatment of recalcitrant condylomata acuminata of the cervix: a randomised placebo controlled trial. Sex Transm. Infect. (2004) 80:216-218.
   PubMed Web of Science ®Google Scholar
• GONCALVES A, CAMERLO J, BUN H et al. Phase II study of a combination of cisplatin, all-trans retinoic acid and IFN-α in squamous cell carcinoma: clinical results and pharmacokinetics. Anticancer Res. (2001) 21:1431-1437.
   PubMed Web of Science ®Google Scholar
• PARK TK, LEE JP, KIM SN, CHOI SM, KUDELKA AP, KAVANAGH JJ: IFN-α2a, 13-cis-retinoic acid and radiotherapy for locally advanced carcinoma of the cervix: a pilot study. Eur. J. Gynaecol. Oncol. (1998) 19:35-38.
   PubMed Web of Science ®Google Scholar
• JUNG W-W, CHUN T, SUL D et al.: Strategies against human papillomavirus infection and cervical cancer. J. Microbiol. (2004) 42:255-266
   PubMed Web of Science ®Google Scholar
• STANLEY MA: Immunobiology of papillomavirus infections. J. Reprod. Immunol. (2001) 52:45-59.
   PubMed Web of Science ®Google Scholar
• RAMOZ N, RUEDA LA, BOUADJAR B, MONTOYA LS, ORTH G, FAVRE M: Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. Nat. Genet. (2002) 32:579-581.
   PubMed Web of Science ®Google Scholar
• LAFFORT C, LE DEIST F, FAVRE M et al.: Severe cutaneous papillomavirus disease after haemopoietic stem-cell transplantation in patients with severe combined immune deficiency caused by common γc cytokine receptor subunit or JAK-3 deficiency. Lancet (2004) 363:2051-2054.
   PubMed Web of Science ®Google Scholar
• CALORE EE, PEREIRA SMM, CAVALIERE MJ: Progression of cervical lesions in HIV seropositive women: a cytological study. Diagn. Cytopathol. (2001) 24:117-119.
   PubMed Web of Science ®Google Scholar
• GONÇALVES MA, DONADI EA: Immune cellular response to hpv: current concepts. Braz. J. Infect. Dis. (2004) 8(1):1-9.
   PubMedGoogle Scholar
• KIM KY, BLATT L, TAYLOR MW: The effects of IFN on the expression of human papillomavirus oncogenes. J. Gen. Virol. (2000) 81:695-700.
   PubMed Web of Science ®Google Scholar
• FRIEDMAN-KIEN A: Management of condylomata acuminata with Alferon N injection, IFN α-n3 (human leukocyte derived). Am. J. Obstet. Gynecol. (1995) 172:1359-1368.
   PubMed Web of Science ®Google Scholar
• REICHMAN R, OAKES D, BONNEZ W et al.: Treatment of condyloma acuminatum with three different IFN-preparations administered parenterally: a double-blind, placebo-controlled trial. J. Infect. Dis. (1990) 162:1270-1276.
   PubMed Web of Science ®Google Scholar
• DOUGLAS JM Jr, ERON LJ, JUDSON FN et al.: A randomized trial of combination therapy with intralesional IFN-α2b and podophyllin versus podophyllin alone for the therapy of anogenital warts. J. Infect. Dis. (1990) 162:52-59.
   PubMed Web of Science ®Google Scholar
• GROSS G, ROGOZINSKI T, SCHOFER H et al.: Recombinant IFN-β gel as an adjuvant in the treatment of recurrent genital warts: results of a placebo-controlled double-blind study in 120 patients. Dermatology (1998) 196:330-334.
   PubMed Web of Science ®Google Scholar
• WILEY DJ, BEUTNER KR: Genital warts. Clin. Evidence (2000) 3:764-774.
   Google Scholar
• CIRELLI R, TYRING SK: IFNs in human papillomavirus infections. Antiviral Res. (1994) 24:191-204.
   PubMed Web of Science ®Google Scholar
• KEAY S, TENG N, EISENBERG M, STORY B, SELLERS PW, MERIGAN TC: Topical IFN for treating condyloma acuminata in women. J. Infect. Dis. (1988) 158:934-939.
   PubMed Web of Science ®Google Scholar
• SYED TA, AHMADPOUR OA, AHMAD SA, AHMAD SH: Human leukocyte IFN-α in a hydrophilic cream versus in a gel for the treatment of genital herpes in males: a placebo-controlled, double-blind, comparative study. J. Dermatol. (1997) 24:564-568.
   PubMedGoogle Scholar
• SYED TA, AHMADPOUR OA: Human leukocyte derived IFN-α in a hydrophilic gel for the treatment of intravaginal warts in women: a placebo-controlled, double-blind study. Int. J. STD& AIDS (1998) 9:769-772.
   PubMed Web of Science ®Google Scholar
• SCHON MP, SCHON M: The small-molecule immune response modifier imiquimod – its mode of action and clinical use in the treatment of skin cancer. J. Invest. Dermatol. (2006) 10:69-76.
   Web of Science ®Google Scholar
• GRUSSENDORF-CONEN EI, JACOBS S, RUBBEN A, DETHLEFSEN U: Topical 5% imiquimod long-term treatment of cutaneous warts resistant to standard therapy modalities. Dermatology (2002) 205:139-145.
   PubMed Web of Science ®Google Scholar
• GARLAND SM: Imiquimod. Curr. Opin. Infect. Dis. (2003) 16:85-89.
   PubMed Web of Science ®Google Scholar
• COX JT: Extensive condyloma acuminata treated with imiquimod 5% cream: a case report. Clin. Exp. Dermatol. (2003) (Suppl. 28) 1:51-54.
   Google Scholar
• JACOBS S, GRUSSENDORF-CONEN EI, ROSENER I, RUBBEN A: Molecular analysis of the effect of topical imiquimod treatment of HPV 2/27/57-induced common warts. Skin Pharmacol. Physiol. (2004) 17:258-266.
   PubMed Web of Science ®Google Scholar
• KREUTER A, BROCKMEYER NH, WEISSENBORN SJ et al.: German competence network HIV/AIDS: 5% imiquimod suppositories decrease the DNA load of intra-anal HPV types 6 and 11 in HIV-infected men after surgical ablation of condylomata acuminata. Arch. Dermatol. (2006) 142:243-244.
   PubMedGoogle Scholar
• FRENCH IH, NASHESKY J: “What is the most effective treatment for external genital warts?” J. Fam. Prac. (2002) 51:313.
   PubMed Web of Science ®Google Scholar
• FIFE KH, FERENCZY A, DOUGLAS JM Jr, BROWN DR, SMITH M, OWENS ML: Treatment of external genital warts in men using 5% imiquimod cream applied three times a week, once daily, twice daily or three times a day. Sex. Transm. Dis. (2001) 28:226-231.
   PubMed Web of Science ®Google Scholar
• EDWARDS L, FERENCZY A, ERON L et al.: Self-administered topical 5% imiquimod cream for external anogenital warts. Arch. Dermatol. (1998) 134:25-30.
   PubMed Web of Science ®Google Scholar
• MAITLAND JE, MAW R: An audit of patients who have received imiquimod cream 5% for the treatment of anogenital warts. Int. J. STD & AIDS (2000) 11:268-270.
   PubMed Web of Science ®Google Scholar
• KREUTER A, HOCHDORFER B, STÜCKER M, ALTMEYER P, WEILAND U, CONANT MA: Treatment of anal intraepithelial neoplasia in patients with acquired HIV with imiquimod 5% cream. J. Am. Acad. Dermatol. (2004) 50:980-981.
   PubMed Web of Science ®Google Scholar
• MACKENZIE-WOOD A, KOSSARD S, DE LAUNEY J, WILKINSON B, OWENS ML: Imiquimod 5% cream in the treatment of Bowen’s disease. J. Am. Acad. Dermatol. (2001) 44:462-470.
   PubMed Web of Science ®Google Scholar
• GUTZMER R, KASPARI M, VOGELBRUCH M et al.: Successful treatment of anogenital Bowen’s disease with the immunomodulator imiquimod, and monitoring of therapy by DNA image cytometry. Br. J. Dermatol. (2002) 147:160-165.
   PubMed Web of Science ®Google Scholar
• THAI KE, SINCLAIR RD: Treatment of Bowen’s disease of the penis with imiquimod. J. Am. Dermatol. (2002) 46:470-471.
   PubMed Web of Science ®Google Scholar
• COOK-BOLDEN F, WEINBERG JM: Topical imiquimod 5% cream in the treatment of Bowen’s disease of the penis. J. Am. Acad. Dermatol. (2002) 46:146-147.
   PubMed Web of Science ®Google Scholar
• DANIELSEN AG, SAND C, WEISMANN K: Treatment of Bowen’s disease of the penis with imiquimod 5% cream. Clin. Exp. Dermatol. (2003) 28(Suppl. 1):7-9.
   PubMed Web of Science ®Google Scholar
• ARLETTE JP: Treatment of Bowen’s disease and erythroplasia of Queyrat. Br. J. Dermatol. (2003) 149(Suppl. 66):43-47.
   PubMed Web of Science ®Google Scholar
• ORENGO I, ROSEN T, GUILL CK: Treatment of squamous cell carcinoma in situ of the penis with 5% imiquimod cream: a case report. J. Am. Acad. Dermatol. (2002) 47:225-228.
   Web of Science ®Google Scholar
• SCHRODER TL, SENGELMANN RD: Squamous cell carcinoma in situ of the penis successfully treated with imiquimod 5% cream. J. Am. Acad. Dermatol. (2002) 46:545-548.
   PubMed Web of Science ®Google Scholar
• MICALI G, NASCA MR, TEDESCHI A: Topical treatment of intraepithelial penile carcinoma with imiquimod. Clin. Exp. Dermatol. (2003) 28(Suppl. 1):4-6.
   PubMed Web of Science ®Google Scholar
• NUNES MDE G, TROPE BM, CAVALCANTI SM, OLIVEIRA LDO H, RAMOS-E-SILVA M: Bowenoid papulosis in a patient with AIDS treated with imiquimod: case report. Acta. Dermatovenerol. Croat. (2004) 12:278-281.
   PubMedGoogle Scholar
• HAIDOPOULOS D, DIAKOMANOLIS E, RODOLAKIS A, VOULGARIS Z, VLACHOS G, INTSAKLIS A: Can local application of imiquimod cream be an alternative mode of therapy for patients with high-grade intraepithelial lesions of the vagina? Int. J. Gynecol. Cancer. (2005) 15(5):898-902.
   PubMed Web of Science ®Google Scholar
• DIAZ-ARRASTIA CR: Clinical efficacy and immune response in high grade lower genital tract intraepithelial lesions treated with topical imiquimod cream 5%. 19th International Papillomavirus Conference. Florianopolis, Brazil, Sept. (2001):183.
   Google Scholar
• TYRING S, ARANY I, STANLEY M et al.: A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. J. Infect. Dis. (1998) 178:551-555.
   PubMed Web of Science ®Google Scholar
• ELFGREN K, BISTOLETTI P, DILLNER L, WALBOOMERS J, MEIJER C, DILLNER J: Conization for cervical intraepithelial neoplasia is followed by disappearance of human papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens. Am. J. Obstet. Gynecol. (1996) 174:937-942.
   PubMed Web of Science ®Google Scholar
• BOLLEN L, TJONG-A-HUNG S, VAN DER VELDEN J et al.: Prediction of recurrent and residual dysplasia by human papillomavirus detection among patients with abnormal cytology. Gynecol. Oncol. (1999) 72:199-201.
   PubMed Web of Science ®Google Scholar
• BEUTNER KR, RICHWALD GA, WILEY DJ, REITANO MV: AMA Expert Panel on External Genital Warts. External genital warts: report of the American Medical Association Consensus Conference. Clin. Infect. Dis. (1998) 27:796-806.
   PubMed Web of Science ®Google Scholar
• WHITE PW, FAUCHER AM, MASSARIOL MJ et al.: Biphenylsulfonacetic acid inhibitors of the human papillomavirus type 6 E1 helicase inhibit ATP hydrolysis by an allosteric mechanism involving tyrosine 486. Antimicrob. Agents Chemother. (2005) 49:4834-4842.
   PubMed Web of Science ®Google Scholar
• RODEN R, WU TC: Preventative and therapeutic vaccines for cervical cancer. Expert Rev. Vaccines. (2003) 2:495-516.
   PubMedGoogle Scholar
• WORLD HEALTH ORGANIZATION. Technical workshop on cellular mediated immunity to HPV: prospects for vaccine development. Geneva, Switzerland, 18-19 April (2005). WHO/IVB/05.21. This publication is available on the Internet at: www.who.int/vaccines-documents/
   Google Scholar
• ZHOU J, SUN XY, STENZEL DJ, FRAZER IH: Expression of vaccinia recombinant HPV16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology (1991) 185:251-257.
   PubMed Web of Science ®Google Scholar
• KIRNBAUER R, BOOY F, CHENG N, LOWY DR, SCHILLER JT: Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. USA. (1992) 89:12180-12184.
   PubMed Web of Science ®Google Scholar
• HARRO CD, PANG YY, RODEN RB et al.: Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl. Cancer Inst. (2001) 93:284-292.
   PubMed Web of Science ®Google Scholar
• EMENY RT, WHEELER CM, JANSEN KU et al.: Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine. J. Virol. (2002) 76:7832-7842.
   PubMed Web of Science ®Google Scholar
• KOUTSKY LA, AULT KA, WHEELER CM et al.: A controlled trial of human papillomavirus type 16 vaccine. New Engl. J. Med. (2002) 347:1645-1651.
   PubMed Web of Science ®Google Scholar
• WORLD HEALTH ORGANIZATION: WHO consultation on human papillomavirus vaccines. Wkly Epidemiol. Rec. (2005) 80:299-301.
   PubMedGoogle Scholar
• MAHDAVI ALI, MONK BRADLEY J: Vaccines against human papillomavirus and cervical cancer: promises and challenges. The Oncologist (2005) 10:528-538.
   PubMed Web of Science ®Google Scholar
• LOWY D R. SCHILLER J T: Prophylactic human papillomavirus vaccines. J. Clin. Invest. (2006) 116:1167-1173.
   PubMed Web of Science ®Google Scholar
• FERRIS D, KOUTSKY L, WEHREN L: Reduction in CIN following prophylactic HPV type 16 vaccination. Gynecol. Oncol. (2005) 96:911a-912a.
   Google Scholar
• NARDELLI-HAEFLIGER D, WIRTHNER D, SCHILLER JT et al.: Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J. Natl. Cancer Inst. (2003) 95:1128-1137.
   PubMed Web of Science ®Google Scholar
• MAO C, KOUTSKY LA, AULT KA et al.: Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet. Gynecol. (2006) 107:18-27.
   PubMed Web of Science ®Google Scholar
• HARPER D M, FRANCO E L, WHEELER C et al.: Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet (2004) 364:1757-1765.
   PubMed Web of Science ®Google Scholar
• VILLA LL, COSTA RLR, PETTA CA et al.: Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. (2005) 6:271-278.
   PubMed Web of Science ®Google Scholar
• SKJELDESTAD FE FOR THE FUTURE II STEERING COMMITTEE: Prophylactic quadrivalent human papillomavirus (HPV) (types 6, 11, 16, 18) L1 virus-like particle (VLP) Vaccine (Gardasil™) reduces cervical intraepithelial neoplasia (CIN) 2/3 risk. Presented at the 43rd Annual Meeting of IDSA. San Francisco (CA) USA (6 – 9 October 2005) San Francisco.
   Google Scholar
• MERCK NEWSROOM: Merck’s investigational vaccine GARDASILTM prevented 100% of cervical pre-cancers and non-invasive cervical cancers associated with HPV types 16 and 18 in new clinical study. Press release 6 Oct (2005).
   Google Scholar
• SATTLER C: Efficacy and safety of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, 18) L1 virus like particle (VLP) vaccine for prevention of cervical dysplasia and external genital lesions (EGL). Abstract presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Washington (DC) USA (16 –19 December 2005).
   Google Scholar
• BARR, E: Gardasil HPV vaccine. Presented at the Centers for Disease Control and Prevention, National Immunization Program meeting of the Advisory Committee on Immunization Practices. Atlanta (GA) USA (10 – 11 February 2005).
   Google Scholar
• SIDDIQUI MA, PERRY CM: Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil). Drugs (2006) 66(9):1263-1271
   PubMed Web of Science ®Google Scholar
• VILLA LL, AULT KA, GIULIANO AR et al.: Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, 18. Vaccine (2006) 24(27-28):5571-5583.
   PubMed Web of Science ®Google Scholar
• HARPER DM, FRANCO EL, WHEELER CM et al.: Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet (2004) 364:1757-1765.
   PubMed Web of Science ®Google Scholar
• DUBIN G: Enhanced immunogenicity of a candidate human papillomavirus (HPV) 16/18 L1 virus like particle (VLP) vaccine with novel AS04 adjuvant in preteens/adolescents. Abstract presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Washington (DC) USA (16 – 19 December 2005).
   Google Scholar
• DUBIN G: Cervarix HPV vaccine. Presented at the Centers for Disease Control and Prevention, National Immunization Program meeting of the Advisory Committee on Immunization Practices. Atlanta (GA) USA (21 – 22 February 2006).
   Google Scholar
• LIU HL, LI WS, LEI T: Expression of human papillomavirus type 16 L1 protein in transgenic tobacco plants. Acta. Biochim. Biophys. Sin. (2005) 37:153-158.
   Google Scholar
• BORYSIEWICZ LK, FIANDER A, NIMAKO M et al.: A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet (1996) 347:1523-1527.
   PubMed Web of Science ®Google Scholar
• DAVIDSON EJ, BOSWELL CM, SEHR P et al.: Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res. (2003) 63:6032-6041.
   PubMed Web of Science ®Google Scholar
• CASSETTI MC, MCELHINEY SP, SHAHABI V et al.: Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine (2004) 22:520-527.
   PubMed Web of Science ®Google Scholar
• HE Z, WLAZLO AP, KOWALCZYK DW et al.: Viral recombinant vaccines to the E6 and E7 antigens of HPV-16. Virology (2000) 270:146-161.
   PubMed Web of Science ®Google Scholar
• LIU DW, TSAO YP, KUNG JT et al.: Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. J. Virol. (2000) 74:2888-2894.
   PubMed Web of Science ®Google Scholar
• NARDELLI-HAEFLIGER D, RODEN RBS, BENYACOUB J et al.: Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralising antibodies in mice. Infect. Immun. (1997) 65:3328-3336.
   PubMed Web of Science ®Google Scholar
• JABBAR IA, FERNANDO GJ, SAUNDERS N et al.: Immune responses induced by BCG recombinant for human papillomavirus L1 and E7 proteins. Vaccine (2000) 18:2444-2453.
   PubMed Web of Science ®Google Scholar
• GUNN GR, ZUBAIR A, PETERS C et al.: Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV16. J. Immunol. (2001) 167:6471-6479.
   PubMed Web of Science ®Google Scholar
• RESSING ME, SETTE A, BRANDT RM et al.: Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J. Immunol (1995) 154:5934-5943.
   PubMed Web of Science ®Google Scholar
• RESSING ME, VAN DRIEL WJ, BRANDT RM et al.: Detection of TH responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J. Immunother. (2000) 23:255-266.
   PubMed Web of Science ®Google Scholar
• MUDERSPACH L, WILCZYNSKI S, ROMAN L et al.: A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin. Cancer Res. (2000) 6:3406-3416.
   PubMed Web of Science ®Google Scholar
• NAKAGAWA M, STITES DP, FARHAT S et al.: Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia. J. Infect. Dis. (1997) 175:927-931.
   Google Scholar
• MELERO I, SINGHAL MC, MCGOWAN P et al.: Immunological ignorance of an E7-encoded cytolytic T lymphocyte epitope in transgenic mice expressing the E7 and E6 oncogenes of human papillomavirus type 16. J. Virol. (1997) 71:3998-4004.
   PubMed Web of Science ®Google Scholar
• ZWAVELING S, FERREIRA MOTA SC et al.: Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J. Immunol. (2002) 169:350-358.
   PubMed Web of Science ®Google Scholar
• BRISTOL JA, ORSINI C, LINDINGER P et al.: Identification of a ras oncogene peptide that contains both CD4+ and CD8+T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization. Cell. Immunol. (2000) 205:73.
   PubMed Web of Science ®Google Scholar
• SCHEURER ME, TORTOLERO-LUNA G, ADLER-STORTHZ K: Human papillomavirus infection: biology, epidemiology, and prevention. Int. J. Gynecol. Cancer (2005) 15:727-746.
   PubMed Web of Science ®Google Scholar
• LACEY CJ, THOMPSON HS, MONTEIRO EF et al.: Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts. J. Infect. Dis. (1999) 179:612-618.
   PubMed Web of Science ®Google Scholar
• DE JONG A, O’NEILL T, KHAN AY et al.: Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine (2002) 20:3456-3464.
   PubMed Web of Science ®Google Scholar
• CHU NR, WU HB, WU T et al.: Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacilli Calmette-Guerin (BCG) hsp65 and HPV16 E7. Clin. Exp. Immunol. (2000) 121:216-225.
   PubMed Web of Science ®Google Scholar
• EINSTEIN MH, KADISH AS, BURK RD et al.: HSP-based immunotherapy (HspE7) for treatment of CIN 3. Gynecol. Oncol. (2005) 96:912a-913a.
   Google Scholar
• OHLSCHLAGER P: Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. J. Virol. (2003) 77(8):4635-4645.
   PubMed Web of Science ®Google Scholar
• YUAN H, ESTES PA, CHEN Y et al.: Immunization with a pentameric L1 fusion protein protects against papillomavirus infection. J. Virol. (2001) 75:7848-7853.
   PubMed Web of Science ®Google Scholar
• SHEDLOCK DJ, WEINER DB: DNA vaccination: antigen presentation and the induction of immunity. J. Leukoc. Biol. (2000) 68:793-806.
   PubMed Web of Science ®Google Scholar
• MONIZ M, LING M, HUNG CF, WU TC: HPV DNA vaccines. Front. Biosci. (2003) 8:D55-D68.
   PubMed Web of Science ®Google Scholar
• PENG S, JI H, TRIMBLE C: Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6. J. Virol. (2004) 78:8468-8476.
   PubMed Web of Science ®Google Scholar
• RODEN RB, LING M, WU TC: Vaccination to prevent and treat cervical cancer. Hum. Pathol. (2004) 35:971-982.
   PubMed Web of Science ®Google Scholar
• KIM JW, HUNG CF, JUANG J et al.: Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther. (2004) 11:1011-1018.
   PubMed Web of Science ®Google Scholar
• PENG S, TOMSON TT, TRIMBLE C, HE L, HUNG CF, WU TC: A combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effects. Gene Ther. (2006) 13(3):257-265.
   PubMed Web of Science ®Google Scholar
• BASU S, SRIVASTAVA PK: Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity. J. Exp. Med. (1999) 189:797-802.
   PubMed Web of Science ®Google Scholar
• SADASIVAN B, LEHNER PJ, ORTMANN B, SPIES T, CRESSWELL P: Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP. Immunity (1996) 5:103-114.
   PubMed Web of Science ®Google Scholar
• KIM TW, HUNG CF, LING M et al.: Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J. Clin. Invest. (2003) 112:109-117.
   PubMed Web of Science ®Google Scholar
• GARCIA F, PETRY KU, MUDERSPACH L et al.: ZYC101a for treatment of highgrade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet. Gynecol. (2004) 103:317-326.
   PubMed Web of Science ®Google Scholar
• DUPUY C, BUZONI-GATEL D, TOUZE A, BOUT D, COURSAGET P: Nasal immunization of mice with human papillomavirus type 16 (HPV16) virus-like particles or with the HPV16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes. J. Virol. (1999) 73:9063-9071.
   PubMed Web of Science ®Google Scholar
• LIU WJ, ZHAO KN, GAO FG, LEGGATT GR, FERNANDO GJ, FRAZER IH: Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy. Vaccine (2001) 20:862-869.
   PubMed Web of Science ®Google Scholar
• STERN PL: Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination. J. Clin. Virol. (2005) 32(Suppl. 1):S72-S81.
   PubMed Web of Science ®Google Scholar
• FERRARA A, NONN M, SEHR P et al.: Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. J. Cancer Res. Clin. Oncol. (2003) 129:521-530.
   PubMed Web of Science ®Google Scholar
• SANTIN AD, BELLONE S, ROMAN JJ, BURNETT A, CANNON MJ, PECORELLI S: Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy. Curr. Pharm. Des. (2005) 11:3485-500.
   PubMed Web of Science ®Google Scholar
• SANTIN AD, BELLONE S, PALMIERI M et al.: HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecol. Oncol. (2006) 100(3):469-478.
   PubMed Web of Science ®Google Scholar
• PEI Y, TUSCHL T: On the art of identifying effective and specific siRNA. Nat. Methods (2006) 3:670-676.
   PubMed Web of Science ®Google Scholar
• TANG S, TAO M, MCCOY JPJR, ZHENG Z-M: The E7 oncoprotein is translated from spliced E6*I transcripts in high-risk human papillomavirus type 16- or 18-positive cervical cancer cell lines via translation reinitiation. J. Virol. (2006) 80:4249-4263.
   PubMed Web of Science ®Google Scholar
• YAMATO K, FEN J, KOBUCHI H et al.: Induction of cell death in human papillomavirus 18-positive cervical cancer cells by E6 siRNA. Cancer Gene Therapy (2006) 13:234-241.
   PubMed Web of Science ®Google Scholar
• ZHANG L, TANG Y, AKBULUT H, ZELTERMAN D, LINTON P-J, DEISSEROTH AB: An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells. Proc. Natl. Acad. Sci. USA (2003) 100:15101-15106.
   PubMed Web of Science ®Google Scholar
• PRE´VILLE X, LADANT D, TIMMERMAN B, LECLERC C: Eradication of established tumors by vaccination with recombinant bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein. Cancer Res. (2005) 65:641-649.
   PubMed Web of Science ®Google Scholar
• KOUTSKY LA, KIVIAT NB: Genital human papillomavirus. In: Sexually Transmitted Diseases, 3rd edn. Holmes KK, Mardh PA, Sparling PF et al. (Eds) McGraw-Hill, New York (1999):347-359.
   Google Scholar
• BURD EM: Human papillomavirus and cervical cancer. Clin. Microbiol. Rev. (2003) 16:1-17.
   Google Scholar
• NATIONAL NETWORK OF STD/HIV PREVENTION TRAINING CENTERS: Genital Human Papillomavirus Infection. June (2004)
   Google Scholar